Genomics technologies such as next-generation sequencing (NGS) and microarrays are accelerating neurogenomics research by revealing the mechanisms behind complex neurological diseases such as Alzheimer’s disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and psychiatric disorders.
The interplay between heritable and nonheritable mutations, epigenetics, and other factors requires NGS-level analyses to increase our understanding. Arrays facilitate large-scale studies of genetic variants associated with neurological diseases. Illumina offers the NGS and microarray tools needed to make genomic neuroscience research possible.
TruSeq Neurodegeneration Panel: This NGS panel covers 118 risk genes associated with common neurodegenerative diseases, including Alzheimer’s disease, Parkinson's disease, ALS, and others.
Infinium PsychArray BeadChip: This array allows researchers to evaluate genetic variants associated with common psychiatric disorders.
Kailos TargetRich PGxComplete: This enrichment-based targeted sequencing research panel covers 43 genes associated with responses to ~100 medications.
Kailos Blue Analytics: These solutions provide sequencing quality assessment, alignment, and variant calling in output formats suitable for use with a variety of reporting solutions.
Neuroscience researchers use NGS to identify variants for a new array designed for ADHD, autism, and schizophrenia studies.Read Interview
Dr. Franco Taroni uses multigene sequencing panels to uncover novel variants associated with metabolic and neurological disorders.Read Interview
Dr. Lachland Jolly and his team are applying functional genomic methods to identify the role of gene variants in intellectual disability.Read Interview
Researchers in the neurogenomics community contributed content for the Neuro Consortium Array, a high-density array featuring over 180,000 markers associated with common neurodegenerative diseases. The array offers a high-throughput genotyping solution for fine mapping and replication of disease-associated variants.Learn More
Through this consortium, scientists selected content for the TruSeq Neurodegeneration Panel based on recent scientific findings. The TruSeq Neurodegeneration Panel offers a high-throughput approach to identifying and validating variants associated with risk for multiple neurodegenerative diseases.Learn More